Clinical data | |
---|---|
Trade names | Trobicin |
Other names | (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one , SPT/SPE/SC/SP[1] |
AHFS/Drugs.com | Monograph |
Routes of administration | IM |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.015.374 |
Chemical and physical data | |
Formula | C14H24N2O7 |
Molar mass | 332.353 g·mol−1 |
3D model (JSmol) | |
Melting point | 184 to 194 °C (363 to 381 °F) |
| |
| |
(what is this?) (verify) |
Spectinomycin, sold under the tradename Trobicin among others, is an antibiotic useful for the treatment of gonorrhea infections.[2] It is given by injection into a muscle.[2]
Common side effects include pain at the area of injection, rash, nausea, fever, and trouble sleeping.[2] Severe allergic reactions may occasionally occur.[2] It is generally safe to use during pregnancy.[2] It may be used by those who are allergic to penicillin or cephalosporins.[2] It is in the aminocyclitol class of drugs and works by stopping the making of protein by certain bacteria.[2]
Spectinomycin was discovered in 1961.[3] It is on the World Health Organization's List of Essential Medicines.[4] It is not available in the United States for human use.[2] It is made from the bacterium Streptomyces spectabilis.[2]